Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Psoriasis is a systemic inflammatory disease with a pathophysiology involving interleukin (IL)‐17. Tofacitinib is an oral Janus kinase inhibitor. Etanercept is a tumour necrosis factor‐α inhibitor used in the treatment of psoriasis. Neither agent inhibits IL‐17 directly. To evaluate correlations between circulating IL‐17A and clinical efficacy in patients with psoriasis treated with tofacitinib or etanercept.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
